To examine the relevance of the persister phenotype in clinical cancer treatments, we derived an mTOR-regulated persister (MP) signature by identifying the common transcriptomic changes in the Torin1-treated vs control and persister vs control comparisons. This evidence concerns the gene MTOR and cancer.